A retrospective cohort study presented by researchers at Mayo Clinic Florida suggests that women aged 45 and older who use menopause hormone therapy may lose more weight on the GLP-1 drug semaglutide than women who do not, according to reporting by Newsweek. The analysis of electronic health records found that hormone therapy users on semaglutide lost an average of 11.6 percent of body weight at 15 months versus 9.7 percent in non-users, a difference that reached statistical significance from nine months of treatment. The findings are observational and do not establish that hormone therapy causes greater weight loss.
The result matters to the peptide therapy and research peptide industry because it points to a patient-selection variable — menopausal status and concomitant hormone use — that clinics, telehealth prescribers and compounding suppliers may need to account for when counseling patients on GLP-1 receptor agonists. It also illustrates how real-world, record-based evidence is now shaping the commercial conversation around incretin therapies faster than randomized trials can report.
What the Mayo Clinic Florida study actually found
The study was a retrospective cohort analysis of electronic health records from overweight and obese women aged 45 and older who had been prescribed either semaglutide, marketed as Ozempic and Wegovy, or tirzepatide, marketed as Mounjaro and Zepbound. The semaglutide group included 2,379 women, while the tirzepatide group included 1,476 women, according to Newsweek’s account of the research.
Researchers used propensity score matching to balance the comparison groups for age, body mass index, prior obesity medication use and Type 2 diabetes status. Among semaglutide users, women taking menopause hormone therapy experienced significantly greater weight loss beginning at nine months. By 15 months, hormone therapy users had lost an average of 11.6 percent of body weight compared with 9.7 percent in non-users; at final follow-up, average weight loss was 11.9 percent versus 10.9 percent.
Larger weight-loss thresholds also favored the hormone therapy group. Fifty-five percent of hormone therapy users lost at least 10 percent of body weight compared with 51 percent of non-users, and 13 percent achieved at least 25 percent weight loss compared with 10 percent of women not taking hormone therapy.
| Measure | Semaglutide users | Tirzepatide users |
|---|---|---|
| Women in cohort | 2,379 | 1,476 |
| Weight loss at 15 months (hormone therapy vs non-users) | 11.6% vs 9.7% | Not statistically significant at later time points |
| Weight loss at final follow-up | 11.9% vs 10.9% | Not reported as significant |
| Share losing ≥10% body weight | 55% vs 51% | Not reported |
| Share losing ≥25% body weight | 13% vs 10% | Not reported |
| First significant divergence | 9 months | First 3 months only |
Tirzepatide shows a weaker, non-significant pattern
Among tirzepatide users, a similar but weaker pattern emerged. Hormone therapy users lost slightly more weight during the first three months of treatment, but the differences were not statistically significant at later time points, according to the Newsweek report.
Dr. Regina Castaneda, the lead author, said the observed association appeared stronger among women using semaglutide than among those using tirzepatide, while cautioning that the study was not designed to directly compare the two medications and that the tirzepatide sample was smaller. She also suggested that tirzepatide’s greater overall weight-loss efficacy may leave less room to detect an additional benefit from hormone therapy — an interpretation offered as a possible explanation rather than a tested finding.
That distinction matters for anyone reading the data commercially. Semaglutide acts on the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors, and their approved products, indications, dosing and labeling differ. Any comparison between the two molecules in this dataset is descriptive, not a head-to-head trial result.
Why it matters for peptide therapy clinics and prescribers
For peptide therapy clinics, medical spas, telemedicine platforms and the compounding supply chain behind them, the study is a reminder that response to incretin-based therapy is heterogeneous. Age, menopausal status, body composition and concurrent medications are all variables that influence how a patient’s weight trajectory unfolds over 12 to 18 months of treatment.
Industry observers note that real-world evidence of this kind tends to move through clinic workflows quickly, because it speaks directly to intake questionnaires and follow-up scheduling. A clinic that already tracks hormone therapy status has a ready-made stratification variable; one that does not may find the finding difficult to apply to its own patient population.
The study does not change any approved indication. Weight loss is not an indication for menopause hormone therapy, as Castaneda stated, and the findings should not be read as a reason to initiate hormone therapy for weight management. The practical relevance is narrower: for women who are already appropriate candidates for hormone therapy, the data offer reassurance rather than a new prescribing rationale.
What remains uncertain: confounding and the case for a randomized trial
Independent expert Dr. Jessica Duncan, chief medical officer at Ivím Health and a board-certified obesity medicine physician, described the results as encouraging and consistent with clinical practice, noting that many midlife women seem to do better on a GLP-1 when menopause symptoms are also being treated.
She also flagged the central methodological limitation. Observational studies cannot fully rule out other explanations, because women on hormone therapy are often healthier, more engaged with their care and better supported, and propensity score matching may not capture all of those differences. A randomized clinical trial would be needed to determine whether hormone therapy directly improves weight-loss outcomes in women taking GLP-1 medications.
Preclinical work offers a biologically plausible mechanism rather than proof. Castaneda cited animal and laboratory evidence suggesting synergy between estrogen signaling and GLP-1 pathways, with estrogen potentially amplifying the appetite-suppressing effects of GLP-1 signaling. Estrogen also influences energy balance, insulin sensitivity and body composition. These are hypotheses generated in preclinical models; they do not demonstrate that the same effect occurs in humans receiving semaglutide.
Research and market context for GLP-1 peptides
The study lands in a market where injectable incretins dominate obesity medicine and where supply, formulation and pricing decisions are made at industrial scale. Semaglutide and tirzepatide are peptide active pharmaceutical ingredients produced through complex synthesis and formulation steps, and finished products combine the API with defined container closure, manufacturing controls and release testing. API quality alone does not establish finished-product quality or regulatory approval, a distinction that becomes critical when clinics source from compounding channels.
For research peptide suppliers and buyers, the same discipline applies. A certificate of analysis reports specified analytical results for a batch; it does not establish clinical safety, efficacy, sterility for a particular use or regulatory approval. Chromatographic purity, typically assessed by HPLC, is not the same as assay content, and neither value alone confirms identity or suitability. Laboratories evaluating GLP-1 peptides for research use should confirm sequence, salt form, molecular weight, batch documentation and storage requirements before treating materials as comparable.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence; readers tracking supplier and logistics developments in the GLP-1 and research peptide supply chain can visit PeptideDDP.com for the latest first-hand information and industry updates.
What comes next
The immediate next step is replication. A prospective, randomized design would be required to separate a true pharmacologic interaction between estrogen signaling and incretin pathways from the healthy-user effect that Duncan described. Until such data exist, the Mayo Clinic Florida results should be treated as a hypothesis-generating signal from matched observational records.
For clinics and telehealth operators, the practical watch items are straightforward: whether subsequent analyses adjust for additional confounders such as socioeconomic status and healthcare engagement, whether the semaglutide signal persists beyond 15 months, and whether any tirzepatide signal emerges in a larger sample. Prescribing decisions remain governed by approved labeling and professional evaluation, and compounded or research-use products should not be represented as approved treatments.
Frequently asked questions
Did the study prove that hormone therapy boosts semaglutide weight loss?
No. The study is a retrospective cohort analysis of electronic health records. It shows an association, not causation, and an independent expert said a randomized trial is needed to determine whether hormone therapy directly improves outcomes.
How much more weight did hormone therapy users lose on semaglutide?
At 15 months, hormone therapy users lost an average of 11.6 percent of body weight versus 9.7 percent in non-users. At final follow-up the figures were 11.9 percent versus 10.9 percent.
Should women start hormone therapy to lose weight on a GLP-1 drug?
No. The lead author stated that weight loss is not an indication for menopause hormone therapy. Hormone therapy decisions should be made with a clinician for appropriate indications.
Why were the tirzepatide results weaker?
The lead author said the study was not designed to compare the two drugs and the tirzepatide sample was smaller, and suggested tirzepatide’s greater overall efficacy may leave less room to detect an added benefit.
Comments